Prostate Cancer Screening

Med Clin North Am. 2018 Mar;102(2):199-214. doi: 10.1016/j.mcna.2017.11.001.


During the prostate-specific antigen-based prostate cancer (PCa) screening era there has been a 53% decrease in the US PCa mortality rate. Concerns about overdiagnosis and overtreatment combined with misinterpretation of clinical trial data led to a recommendation against PCa screening, resulting in a subsequent reversion to more high-risk disease at diagnosis. Re-evaluation of trial data and increasing acceptance of active surveillance led to a new draft recommendation for shared decision making for men aged 55 to 69 years old. Further consideration is needed for more intensive screening in men with high-risk factors. PCa screening significantly reduces PCa morbidity and mortality.

Keywords: History of prostate cancer screening; PSA; Prostate; Prostate cancer; Prostate cancer screening; Prostate cancer screening guidelines; Prostate-specific antigen; United States Preventive services Task Force.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / blood
  • Decision Making
  • Early Detection of Cancer* / statistics & numerical data
  • Humans
  • Male
  • Mass Screening / statistics & numerical data
  • Medical Overuse
  • Patient Participation
  • Primary Health Care
  • Prostate-Specific Antigen / blood*
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / epidemiology
  • United States / epidemiology


  • Biomarkers, Tumor
  • Prostate-Specific Antigen